While PARP1 inhibitors represent a novel approach to cancer therapy, researchers have cautioned that they may prove insufficient for treating late-stage metastatic cancers.
Aínda que os inhibidores do encima PARP1 representan un novo enfoque para a terapia do cancro, os investigadores advirten que poden ser insuficientes para a tratar cancros metastáticos en fases terminais.